Article
Multidisciplinary Sciences
Emilie H. Zobel, Rasmus S. Ripa, Bernt J. von Scholten, Viktor Rotbain Curovic, Andreas Kjaer, Tine W. Hansen, Peter Rossing, Joachim Storling
Summary: Liraglutide has been found to exert anti-inflammatory effects in the peripheral blood mononuclear cells of individuals with type 2 diabetes, with no significant presence of GLP-1 receptor expression. Further research is needed to clarify the indirect effects of liraglutide on PBMC gene expression and establish the anti-inflammatory potential of GLP-1 receptor agonists.
SCIENTIFIC REPORTS
(2021)
Article
Endocrinology & Metabolism
Kristina S. Boye, Jeremie Lebrec, Anne Dib, Elke Heitmann, Marco Orsini Federici, Maria Yu, Helene Sapin, Annabel Barrett, Bruno Guerci, Francesco Giorgino, Martin Fuechtenbusch, Luis-Emilio Garcia-Perez
Summary: This study reports the health-related patient-reported outcomes (PROs) of patients with T2D initiating their first injectable glucose-lowering medication (GLM) with two common GLP-1RAs. The results show that dulaglutide had more significant improvements in PRO scores compared to liraglutide, and patients were more satisfied with the injection device of dulaglutide.
DIABETES OBESITY & METABOLISM
(2023)
Article
Cardiac & Cardiovascular Systems
Damien Denimal, Victoria Bergas, Jean-Paul Pais-de-Barros, Isabelle Simoneau, Laurent Demizieux, Patricia Passilly-Degrace, Benjamin Bouillet, Petit Jean-Michel, Alexia Rouland, Amandine Bataille, Laurence Duvillard, Bruno Verges
Summary: The study investigates the effects of the GLP-1 receptor agonist liraglutide on the levels of dihydroceramides (DhCer) and ceramides (Cer) in type 2 diabetes (T2D) patients. Results show that liraglutide reduces plasma levels of DhCer and Cer species, which may contribute to the cardiovascular benefits observed. Additionally, the decrease in plasma DhCer levels is independently associated with the reduction in liver fat content and insulin resistance.
CARDIOVASCULAR DIABETOLOGY
(2023)
Article
Endocrinology & Metabolism
Bruno Guerci, Francesco Giorgino, Helene Sapin, Kristina Boye, Jeremie Lebrec, Marco Orsini Federici, Elke Heitmann, Anne Dib, Martin Fuchtenbusch, Luis-Emilio Garcia-Perez
Summary: The TROPHIES observational study aims to estimate the duration of treatment on dulaglutide or liraglutide without significant treatment changes in patients with type 2 diabetes. The study found that both medications resulted in improved glycemic control, weight loss, and high persistence rates.
DIABETES OBESITY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Mariam Alatrach, Christina Agyin, Carolina Solis-Herrera, Olga Lavryneko, John Adams, Amalia Gastaldelli, Curtis Triplitt, Ralph A. DeFronzo, Eugenio Cersosimo
Summary: This study found that SGLT2 inhibitors have an effect on the increase of endogenous glucose production (EGP) in patients with type 2 diabetes after oral glucose intake. Despite elevated plasma insulin and glucagon, the stimulation of EGP was observed, suggesting that additional factors may be involved.
Article
Multidisciplinary Sciences
Joseph B. Lerman, Stephanie N. Giamberardino, Adrian F. Hernandez, G. Michael Felker, Svati H. Shah, Robert W. McGarrah
Summary: This study analyzed data from the FIGHT trial and found that metabolic derangements in patients with HFrEF were associated with functional outcomes and prognosis, especially in those with T2DM.
SCIENTIFIC REPORTS
(2022)
Article
Endocrinology & Metabolism
Jennifer B. Green, Peter Merrill, Yuliya Lokhnygina, Robert J. Mentz, Joakim Alfredsson, Rury R. Holman, EXSCEL Study Grp
Summary: This study aimed to examine sex differences in patients with type 2 diabetes (T2D) and compared the characteristics and outcomes between those treated with exenatide and placebo. The results showed that female patients had differences in age, duration of diabetes, and coronary artery disease compared to male patients, but had worse metabolic risk profiles and lower use of cardioprotective medications. Despite these factors, women had significantly lower rates of cardiovascular events.
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
William H. Polonsky, Francesco Giorgino, Julio Rosenstock, Katherine Whitmire, Elisheva Lew, Mathieu Coudert, Agustina Alvarez, Charlie Nicholls, Rory J. McCrimmon
Summary: This study aimed to assess the efficacy and safety of iGlarLixi compared to BIAsp 30 in patients with T2D, and the impact on patient-reported outcomes. The results showed that iGlarLixi had greater improvements in TRIM-D scores and GTEE scores compared to BIAsp 30.
DIABETES OBESITY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Lin Zhang, Yanjin Hu, Yu An, Qiu Wang, Jia Liu, Guang Wang
Summary: This study used a lipidomic approach to investigate lipid changes in response to treatment with exenatide in T2DM patients. The results showed that exenatide treatment can improve lipid metabolism, especially sphingomyelins, lysophosphatidylcholines, and lysophosphatidylethanolamines.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Hao Wu, Zongshi Lu, Runyao Chen, Quanfang Cai, Miaomiao Wang, Liting Zhang, Zhiming Zhu
Summary: This study identified AGI use, concomitant gastrointestinal diseases, higher TSH levels, and female sex as independent risk factors for the gastrointestinal side effects of liraglutide treatment in patients with T2DM. Further research is needed to understand these interactions.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Health Care Sciences & Services
Jeppe Eriksen, Ann Bygholm, Signe Hudtloff Nielsen, Pernille Bertelsen
Summary: This study examined the experiences of newly diagnosed type-2 diabetes patients when using a newly developed patient-reported outcome (PRO) questionnaire in clinical practice. The PRO questionnaire prompted reflections, motivated self-management activities, and facilitated structured and effective conversations between patients and healthcare professionals. However, the questionnaire lacked response options, leading to concerns and uncertainty among patients. Overall, the informants found the PRO questionnaire and data meaningful and useful.
Article
Pharmacology & Pharmacy
Han Liu, Suohui Zhang, Zequan Zhou, Mengzhen Xing, Yunhua Gao
Summary: In this study, two-layer sustained-release microneedles (TS-MNs) were successfully fabricated for the sustained delivery of exenatide (EXT). The TS-MNs showed good mechanical strength and could penetrate the skin for drug release. Moreover, the TS-MNs retained high drug activity during storage and had high relative bioavailability.
Article
Multidisciplinary Sciences
Wan-Chun Huang, Yen-Chou Chen, Chung-Hsuen Wu, Yu Ko
Summary: In high CVD risk T2DM patients, liraglutide treatment was associated with reduced risk of composite CVD outcomes, nonfatal stroke, and all-cause mortality compared to basal insulin. Liraglutide users had lower inpatient, ER, and total medical costs, but higher outpatient, total pharmacy, and total costs.
SCIENTIFIC REPORTS
(2021)
Review
Pharmacology & Pharmacy
Athanasia K. Papazafiropoulou, Andreas Melidonis, Stavros Antonopoulos
Summary: In recent years, research has shown that GLP-1 receptor agonists and SGLT2 inhibitors not only improve glycemic control in diabetic patients, but also have positive effects on cardiovascular risk factors and weight. These drugs may also have benefits for non-diabetic patients.
CURRENT PHARMACEUTICAL DESIGN
(2021)
Article
Medicine, General & Internal
David M. Nathan, GRADE Study Res Grp, John M. Lachin, Ashok Balsubramanyam, Henry B. Burch, John B. Buse, Nicole M. Butera, Robert M. Cohen, Jill P. Crandall, Steven E. Kahn, Heidi Krause-Steinrauf, Mary E. Larkin, Neda Rasouli, Margaret Tiktin, Deborah J. Wexler, Naji Younes
Summary: In this trial, all four glucose-lowering medications added to metformin were effective in reducing glycated hemoglobin levels. Glargine and liraglutide showed modestly superior efficacy in achieving and maintaining target glycated hemoglobin levels.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
David R. Boulware, Thomas A. Murray, Jennifer L. Proper, Christopher J. Tignanelli, John B. Buse, David M. Liebovitz, Jacinda M. Nicklas, Kenneth Cohen, Michael A. Puskarich, Hrishikesh K. Belani, Lianne K. Siegel, Nichole R. Klatt, David J. Odde, Amy B. Karger, Nicholas E. Ingraham, Katrina M. Hartman, Via Rao, Aubrey A. Hagen, Barkha Patel, Sarah L. Fenno, Nandini Avula, Neha Reddy, Spencer M. Erickson, Sarah Lindberg, Regina Fricton, Samuel Lee, Adnin Zaman, Hanna G. Saveraid, Walker J. Tordsen, Matthew F. Pullen, Nancy E. Sherwood, Jared D. Huling, Carolyn T. Bramante
Summary: SARS-CoV-2 vaccine-boosted participants experienced the least severe symptoms during COVID-19, and their symptoms improved the fastest over time. Vaccination against SARS-CoV-2 was found to be associated with reduced symptom severity in a sample of low to moderate risk adults enrolled in an outpatient COVID-19 treatment trial. Booster shots further reduced symptom severity.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Medicine, Research & Experimental
Seth A. Berkowitz, Gina R. Kruse, Katharine A. Ball Ricks, Jessica Burch, Ethan Ouimet, Beth Kitzis, Colleen Forrest, Jean Terranova, Paul W. Stewart, John B. Buse, Thomas C. Keyserling, Deborah J. Wexler, Linda M. Delahanty
Summary: This article describes a trial protocol to assess whether medically tailored meals plus lifestyle intervention can improve hemoglobin A1c and participant-reported outcomes compared to a food subsidy for adults with both type 2 diabetes and food insecurity. The trial aims to enroll 200 participants and will use a pragmatic design with random assignment to different interventions. The primary outcome is hemoglobin A1c at 6 months. The results will inform clinical management of food insecurity in the context of type 2 diabetes.
CONTEMPORARY CLINICAL TRIALS
(2023)
Editorial Material
Endocrinology & Metabolism
Steven E. Kahn, Cheryl A. M. Anderson, John B. Buse, Elizabeth Selvin, Sonia Y. Angell, Vanita R. Aroda, Jessica R. Castle, Alice Y. Y. Cheng, Thomas Danne, Justin B. Echouffo-Tcheugui, Jose C. Florez, Meghana D. Gadgil, Amalia Gastaldelli, Jennifer B. Green, Ania M. Jastreboff, Alka M. Kanaya, Namratha R. Kandula, Csaba P. Kovesdy, Neda Laiteerapong, Kristen J. Nadeau, Rodica Pop-Busui, Camille E. Powe, Casey M. Rebholz, Michael R. Rickels, Naveed Sattar, Jonathan E. Shaw, Emily K. Sims, Kristina M. Utzschneider, Adrian Vella, Cuilin Zhang
Editorial Material
Endocrinology & Metabolism
Steven E. Kahn, Cheryl A. M. Anderson, John B. Buse, Elizabeth Selvin
Article
Endocrinology & Metabolism
Shweta Pathak, Kristina Kearin, Anna R. Kahkoska, Kathryn A. Fuller, Bradley Staats, Joseph Albright, Til Sturmer, John B. Buse, Benjamin Y. Urick
Summary: A policy change by a commercial insurer expanded coverage of continuous glucose monitoring (CGM) through the pharmacy benefit, leading to increased utilization of CGM. The study found that CGM use significantly increased after the policy change, especially among type 1 diabetes mellitus (T1DM) patients. The findings suggest that the policy change had a positive impact on CGM utilization.
DIABETES TECHNOLOGY & THERAPEUTICS
(2023)
Article
Computer Science, Interdisciplinary Applications
Elena Casiraghi, Rachel Wong, Margaret Hall, Ben Coleman, Marco Notaro, Michael D. Evans, Jena S. Tronieri, Hannah Blau, Bryan Laraway, Tiffany J. Callahan, Lauren E. Chan, Carolyn T. Bramante, John B. Buse, Richard A. Moffitt, Til Sturmer, Steven G. Johnson, Yu Raymond Shao, Justin Reese, Peter N. Robinson, Alberto Paccanaro, Giorgio Valentini, Jared D. Huling, Kenneth J. Wilkins
Summary: Healthcare datasets from Electronic Health Records are valuable for assessing associations between patients' predictors and outcomes. However, missing values are common in these datasets, and removing them may introduce bias. Multiple imputation algorithms have been proposed to recover missing information, but there is no consensus on which algorithm works best. Choosing algorithm parameters and data-related modeling choices is also challenging.
JOURNAL OF BIOMEDICAL INFORMATICS
(2023)
Article
Medicine, Research & Experimental
Andrea L. Cherrington, Heidi Krause-Steinrauf, Vanita Aroda, John B. Buse, Basma Fattaleh, Stephen P. Fortmann, Stephanie Hall, Sophia H. Hox, Alexander Kuhn, Tina Killean, Amy Loveland, Lawrence S. Phillips, Analyn Uy Jackson, Andrea Waltje, M. Diane McKee
Summary: This study successfully recruited a diverse population of individuals with relatively new onset of type 2 diabetes mellitus, relying heavily on the use of Electronic Health Record for participant screening. A comprehensive approach to recruitment with frequent monitoring was critical for achieving the recruitment goal.
Editorial Material
Endocrinology & Metabolism
Steven E. Kahn, Cheryl A. M. Anderson, Mark A. Atkinson, George L. Bakris, John B. Buse, Frank B. Hu, Stephen S. Rich, Matthew C. Riddle, Elizabeth Selvin
Article
Endocrinology & Metabolism
John B. Buse, Helene Nordahl Christensen, Brian J. Harty, Julie Mitchell, Benjamin P. Soule, Emily Zacherle, Mark Cziraky, Vincent J. Willey
Summary: SEPRA is an ongoing pragmatic clinical trial that aims to compare the effects of once-weekly subcutaneous semaglutide with standard care in patients with type 2 diabetes. It collects data from routine clinical practice to support decision-making by clinicians, payers, and policy makers. Key outcomes of the study include glycemic control, weight loss, healthcare utilization, and patient-reported outcomes.
BMJ OPEN DIABETES RESEARCH & CARE
(2023)
Article
Medicine, Research & Experimental
John B. Buse, Christopher P. Austin, S. Claiborne Johnston, Freda Lewis-Hall, Andrew N. March, Carolyn K. Shore, Pamela Tenaerts, Joni L. Rutter
Summary: Clinical trial processes are inefficient and costly, hindering the translation of medical discoveries into treatments. A group of experts developed a framework for clinical trial site readiness based on existing qualifications. The framework includes six domains and aims to reduce inefficiencies, improve reach, and benefit trial sponsors, organizations, participants, and the public. Novice and experienced sites can use the framework for preparation, assessment, and engagement with stakeholders.
JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE
(2023)
Article
Medicine, Research & Experimental
Jessica A. Regan, Robert J. Mentz, Maggie Nguyen, Jennifer B. Green, Lauren K. Truby, Olga Ilkayeva, Christopher B. Newgard, John B. Buse, Harald Sourij, C. David Sjostrom, Naveed Sattar, Robert W. Mcgarrah, Yinggan Zheng, Darren K. Mcguire, Eberhard Standl, Paul Armstrong, Eric D. Peterson, Adrian F. Hernandez, Rury R. Holman, Svati H. Shah
Summary: This study reveals the heterogeneity of major adverse cardiovascular event (MACE) risk in individuals with type 2 diabetes mellitus (T2D) and identifies circulating metabolites reflecting mitochondrial dysfunction that can predict incident MACE. These metabolites remain associated with MACE in multivariate models and show favorable changes with exenatide therapy. The findings suggest that these biomarkers may improve cardiovascular risk prediction models and highlight emerging risk mechanisms.
Article
Psychology, Clinical
Larissa Vierl, Susanne Hoerz-Sagstetter, Cord Benecke, Carsten Spitzer, Florian Juen
Summary: This study compares two widely used questionnaires based on psychodynamic theories for assessing personality functioning (PF), finding that while highly correlated, they tap into distinct domains of PF. Exploratory Graph Analysis (EGA) and bootEGA were used to explore the dimensionality and stability of the questionnaires. These findings have important implications for clinical and scientific practice.
JOURNAL OF PERSONALITY ASSESSMENT
(2023)
Article
Medicine, Research & Experimental
Nandini Avula, Dustin Kakach, Christopher J. Tignanelli, David M. Liebovitz, Jacinda M. Nicklas, Kenneth Cohen, Michael A. Puskarich, Hrishikesh K. Belani, John B. Buse, Nichole R. Klatt, Blake Anderson, Amy B. Karger, Katrina M. Hartman, Barkha Patel, Sarah L. Fenno, Neha V. Reddy, Spencer M. Erickson, David R. Boulware, Thomas A. Murray, Carolyn T. Bramante
Summary: The COVID-19 pandemic has led to the advancement of decentralized clinical trials (DCT). DCTs have proved to be an effective and pragmatic method for assessing health outcomes during the pandemic. This report highlights the successful implementation of the COVID-OUT trial, which utilized decentralized strategies to rapidly deliver study drugs and remotely monitor participant outcomes.
JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE
(2023)
Article
Medicine, Research & Experimental
Lauren E. Dang, Edwin Fong, Jens Magelund Tarp, Kim Katrine Bjerring Clemmensen, Henrik Ravn, Kajsa Kvist, John B. Buse, Mark van der Laan, Maya Petersen
Summary: This study presents three designs for evaluating the difference in risk of major adverse cardiovascular events between oral semaglutide and standard-of-care. Simulation results show that Designs 1 and 2 perform similarly, while Design 3 integrates external controls in 84% of cross-validation folds. The estimated risk difference using Design 3 is -1.53%-points.
JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE
(2023)
Article
Medicine, Research & Experimental
Mustafa Tosur, Laura Gandolfo, Ashok Balasubramanyam, Rochelle N. Naylor, Toni I. Pollin, Neda Rasouli, Sara J. Cromer, John B. Buse, Maria J. Redondo
Summary: The incidence of diabetes in underrepresented racial and ethnic groups is increasing and has worse outcomes compared to non-Hispanic White individuals. This study aimed to recruit a diverse study population, however, the participation of underrepresented groups was low. Strategies to enhance their recruitment and retention are needed.
JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE
(2023)